Menu

Parts of U.S. Saw an Increase in Zika-Linked Birth Defects in 2016

The rise occurred in areas with confirmed local transmission, according to a new CDC report. 

Jan 26, 2018
Katarina Zimmer

ISTOCK, NECKAEV-KON In the latter half of 2016, US jurisdictions with known local transmission of Zika saw a 21 percent increase in birth defects potentially linked to the virus, according to a report published today (January 26) by the Centers for Disease Control and Prevention (CDC).

“This finding underscores the importance of surveillance for birth defects potentially related to Zika virus infection and the need for continued monitoring in areas at risk for Zika transmission and exposure,” the authors write in the report.

The CDC team searched for cases of Zika-associated birth defects, such as microcephaly, in just under one million births that occured across 15 US states and territories in 2016. These included areas with documented cases of local Zika transmission (Puerto Rico, southern Florida, and a portion of southern Texas) and locations with confirmed instances of travel-associated Zika infections.

The researchers found that three of every 1,000 babies born in those areas had a birth defect that could have been linked to Zika infection in their mothers. When they specifically focused on areas with local transmission and excluded birth defects with weaker links to Zika, such as neural tube defects and other early brain malformations, they found a statistically significant increase in the number of Zika-linked birth defects in the second half of 2016 compared to the first.  

The study authors expect another potential increase of Zika-related birth defects in 2017, given that the peak of confirmed local transmission occurred in the second half of 2016.

Brenda Fitzgerald, director of the CDC, and her colleagues argue that these numbers might only represent a fraction of the full effect of congenital Zika virus infections. “[S]ome healthy infants born following pregnancies complicated by Zika may have developmental problems that become evident later,” they write in a JAMA commentary. “[O]ngoing surveillance is needed to determine the extent to which congenitally exposed infants without apparent birth defects will experience similar or other developmental issues.”

The number of laboratory-confirmed Zika cases has declined since 2016, according to CDC data. Some scientists believe that this is because much of the population in the Americas developed immunity to the virus, Science reported last year.

Nevertheless, there are ongoing efforts to develop Zika vaccines to prevent future epidemics and to control populations of Zika-carrying mosquito species. 

See “Zika Vaccine Shows Promise in Early Clinical Trial

CENTERS FOR DISEASE CONTROL AND PREVENTION

 

April 2019

Will Car T Cells Smash Tumors?

New trials take the therapy beyond the blood

Marketplace

Sponsored Product Updates

Getting More Consistent Results by Knowing the Quality of Your Protein
Getting More Consistent Results by Knowing the Quality of Your Protein
Download this guide from NanoTemper to learn how to identify and evaluate the quality of your protein samples!
Myth Busting: The Best Way to Use Pure Water in the Lab
Myth Busting: The Best Way to Use Pure Water in the Lab
Download this white paper from ELGA LabWater to learn about the role of pure water in the laboratory and the advantages of in-house water purification!
Shimadzu's New Nexera UHPLC Series with AI and IoT Enhancements Sets Industry Standard for Intelligence, Efficiency and Design
Shimadzu's New Nexera UHPLC Series with AI and IoT Enhancements Sets Industry Standard for Intelligence, Efficiency and Design
Shimadzu Corporation announces the release of the Nexera Ultra High-Performance Liquid Chromatograph series, incorporating artificial intelligence as Analytical Intelligence, allowing systems to detect and resolve issues automatically. The Nexera series makes lab management simple by integrating IoT and device networking, enabling users to easily review instrument status, optimize resource allocation, and achieve higher throughput.
IDT lowers genomic barriers with powerful rhAmpSeq™ targeted sequencing system
IDT lowers genomic barriers with powerful rhAmpSeq™ targeted sequencing system
Increasing accuracy and reducing cost barriers, IDT’s innovative system delivers simple and cost-effective amplicon sequencing